Paper Details

  1. Home
  2. Paper Details

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Author: FrosinaGuido, HalatschMarc-Eric, Karpel-MasslerGeorg, KastRichard E, RykenTimothy, SkuliNicolas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explores the EIS Regimen, a treatment protocol using six older medicines to inhibit epithelial to mesenchymal transition (EMT) in glioblastoma. EMT is a crucial factor in the lethality of glioblastoma, contributing to therapy resistance and tumor migration. EIS Regimen uses six drugs with known ancillary properties to block key EMT triggers: itraconazole for Hedgehog signaling, metformin for AMPK, naproxen for Rac1, pirfenidone for TGF-beta, quetiapine for RANKL, and rifampin for Wnt. While each drug has a good safety profile individually, further studies are needed to evaluate the safety and efficacy of their combination in the EIS Regimen.
Paper Details　
Original Abstract of the Article :
This paper outlines a treatment protocol to run alongside of standard current treatment of glioblastoma- resection, temozolomide and radiation. The epithelial to mesenchymal transition (EMT) inhibiting sextet, EIS Regimen, uses the ancillary attributes of six older medicines to impede EMT during gli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617382/

データ提供：米国国立医学図書館（NLM）

Blocking Epithelial-to-Mesenchymal Transition in Glioblastoma

This paper presents a treatment protocol called the EIS Regimen, designed to inhibit epithelial-to-mesenchymal transition (EMT) in glioblastoma. The EIS Regimen uses six repurposed drugs to target key signaling pathways involved in EMT, which is a process that contributes to cancer's aggressive behavior.

Targeting EMT in Glioblastoma

The study proposes a novel approach to treating glioblastoma by inhibiting EMT. The EIS Regimen aims to block EMT by using a combination of drugs with known ancillary attributes that target specific signaling pathways. The authors argue that inhibiting EMT could help to prevent glioblastoma's spread and resistance to therapy.

New Hope for Glioblastoma Treatment

This research offers a potential new strategy for treating glioblastoma. The EIS Regimen, by targeting EMT, could help to improve patient outcomes and prolong survival. Further research is needed to evaluate the effectiveness and safety of this innovative approach.

Dr. Camel's Conclusion

Glioblastoma, like a shifting desert sand dune, is a formidable foe. The EIS Regimen offers a new weapon in the fight against this deadly cancer. By targeting EMT, this innovative approach aims to disrupt the cancer's aggressive behavior and improve patient outcomes.

Date :
  1. Date Completed n.d.
  2. Date Revised 2019-11-20
Further Info :

Pubmed ID

28977822

DOI: Digital Object Identifier

PMC5617382

Related Literature

Article Analysis
・Side Effects of naproxen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.